Veteran pharmaceutical executive to lead AOP Health’s U.S. expansion and commercial launch of Rapiblyk™
AOP Orphan Pharmaceuticals GmbH (AOP Health), a global leader in integrated therapy solutions for rare diseases and critical care, is pleased to announce the appointment of John Kimmet as U.S. General Manager. John brings more than 25 years of leadership experience, with a strong track record of success in the pharmaceutical industry.
John has held senior executive roles at leading pharmaceutical companies, including Bristol-Myers Squibb / Celgene and Eagle Pharmaceuticals. Most recently, he served as a Strategic Advisor to the Board at Copilot Hub Services. His strategic insights and operational expertise make him uniquely suited to lead AOP Health’s expansion into the U.S. market.
As U.S. General Manager, John will lead critical efforts to set up and grow AOP Health’s U.S. presence, with a focus on overseeing the commercial launch of Rapiblyk™ (landiolol), an ultra-short-acting beta-1 selective adrenergic receptor blocker for critical care use. His role will also establish the infrastructure necessary to support healthcare professionals and the patients they serve.
To drive this effort, AOP Health is actively building out its U.S. field organisation. The company has hired a team of Medical Science Liaisons, National Account Managers, and Key Account Managers to provide dedicated support to providers nationwide.
We are thrilled to welcome John to AOP Health. His deep industry knowledge and commitment to patient-centric innovation align perfectly with our mission. Under his leadership, we look forward to advancing our U.S. operations and expanding access to our therapies.
Jean-Michel Quinot
Chief Operating Officer AOP Health
Source & Image Credit: AOP Health
